migraine
Conditions
Interventions
We prescribe suvorexant to migraine patient with innsomnia About 80 cases are made a target in 5 years (until March 30, 2020) in this research period of the execution. The prescription amount confor
Sponsors
Tokai University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: migraineurs with insomnia are diagnized by ICHD-IIIbeta and ICSD-2
Exclusion criteria
Exclusion criteria: Less than 19 years old Patients who have got serious adverse events by suvorexant CYP3A inhibitors Narcolepsy, Catalepsy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The evaluation items * The degree of sleepless serious illness by the suvorexant internal use (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS) Evaluation schedule * The degree of sleepless serious illness before suvorexant internal use (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS) * The degree of sleepless serious illness for the 1st week after suvorexant internal use (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS) * 1 month later of suvorexant internal use, the degree of sleepless serious illness (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS) * 3 months later of suvorexant internal use, the degree of sleepless serious illness (Athens score and ISI - J) and the one degree of headache serious illness value (HIT-6 and MIDAS) | — |
Countries
Japan
Contacts
Public ContactEiichiro Nagata
Tokai University School of Medicine Neurology
Outcome results
None listed